Abstract
Purpose
To assess the long-term outcomes and complications of patients with uveitis from juvenile idiopathic arthritis (JIA) treated with adalimumab.
Methods
Prospective interventional case series. All patients who underwent treatment with adalimumab for JIA and anterior uveitis were prospectively included in the study. The anterior chamber inflammation was evaluated according to the Standardization of Uveitis Nomenclature criteria.
Results
Twenty-one patients (16 females, five males, 38 eyes) were included in the study. Mean age of patients at referral was 11.1 ± 3.8 (5–17) years. Before initiation of treatment, mean duration of arthritis was 7.0 ± 5.5 (median, 6) months, mean duration of uveitis was 7.0 ± 4.4 (median, 7) months. Oligoarticular arthritis was present in 15 cases (71 %), polyarticular arthritis in six cases (28 %). After a mean follow-up of 18.2 ± 7.7 (9–41) months, resolution of anterior chamber inflammation was obtained in 29/38 eyes (76 %). The anterior uveitis flare rate during the 12 months prior to enrollment was 1.6 ± 0.4/year, and was reduced during adalimumab treatment to 0.7 ± 0.3/year (p < 0.001). A significant decrease of the number of relapses/month was present after onset of treatment with adalimumab (0.18 ± 0.2 before versus 0.02 ± 0.1 after treatment onset, p < 0.001). No significant correlation was found between relapse number and age, sex, type of JIA and doses of previous steroid treatment (p > 0.05).
Conclusion
Adalimumab showed to be effective and relatively safe for treatment of JIA-associated uveitis.
Similar content being viewed by others
References
Levinson JE, Wallace CA (1992) Dismantling the pyramid. J Rheumatol 33(Suppl):6–10
Ruperto N, Levinson JE, Ravelli A, Shear ES, Link Tague B, Murray K, Martini A, Giannini EH (1997) Long term health outcomes and quality of life in American and Italian inception cohorts of patients with juvenile rheumatoid arthritis. I. Outcome status. J Rheumatol 24:945–951
Kanski JJ (1990) Juvenile arthritis and uveitis. Surv Ophthalmol 34:253–267
Kotaniemi K, Savolainen A, Karma A, Aho K (2003) Major review. Recent advances in uveitis of juvenile idiopathic arthritis. Surv Ophthalmol 48:489–502
Zannin ME, Buscain I, Vittadello F, Martini G, Alessio M, Orsoni JG, Breda L, Rigante D, Cimaz R, Zulian F (2012) Timing of uveitis onset in oligoarticular juvenile idiopathic arthritis (JIA) is the main predictor of severe course uveitis. Acta Ophthalmol 90:91–95
Santos Lacomba M, Marcos Martín C, Gallardo Galera JM, Gómez Vidal MA, Collantes Estévez E, Ramírez Chamond R, Omar M (2001) Aqueous humor and serum tumor necrosis factor-alpha in clinical uveitis. Ophthalmic Res 33:251–255
Smith JR, Levinson RD, Holland GN, Jabs DA, Robinson MR, Whitcup SM, Rosenbaum JT (2001) Differential efficacy of tumor necrosis factor inhibition in the management of inflammatory eye disease and associated rheumatic disease. Arthritis Rheum 45:252–257
Lovell D (2004) Biological agents for the treatment of juvenile rheumatoid arthritis: current status. Paediatric Drugs 6:137–146
Gartlehner G, Hansen RA, Jonas BL, Thieda P, Lohr KN (2008) Biologics for the treatment of juvenile idiopathic arthritis: a systemic review and critical analysis of the evidence. Clin Rheumatol 27:67–76
Beresford MW, Baildam EM (2009) New advances in the management of juvenile idiopathic arthritis. 2: the era of biologicals. Arch Dis Child Educ Pract Ed 94:151–156
Lovell DJ, Reiff A, Ilowite NT, Wallace CA, Chon Y, Lin SL, Baumgartner SW, Giannini EH, Pediatric Rheumatology Collaborative Study Group (2008) Safety and efficacy of up to eight years of continuous etanercept therapy in patients with juvenile idiopathic arthritis. Arthritis Rheum 58:1496–1504
Horneff G, De Bock F, Foeldvari I, Girschick HJ, Michels H, Moebius D, Schmeling H, German and Austrian Paediatric Rheumatology Collaborative Study Group (2009) Safety and efficacy of combination of etanercept and methotrexate compared to treatment with etanercept only in patients with juvenile idiopathic arthritis (JIA): preliminary data from the German registry. Ann Rheum Dis 68:519–525
Prince FH, Twilt M, ten Cate R, van Rossum MA, Armbrust W, Hoppenreijs EP, van Santen-Hoeufft M, Koopman-Keemink Y, Wulffraat NM, van Suijlekom-Smit LW (2009) Long-term follow-up on effectiveness and safety of etanercept in JIA: the Dutch national register. Ann Rheum Dis 68:635–641
Tynjälä P, Lindahl P, Honkanen V, Lahdenne P, Kotaniemi K (2007) Infliximab and etanercept in the treatment of chronic uveitis associated with refractory juvenile idiopathic arthritis. Ann Rheum Dis 66:548–550
Kahn P, Weiss M, Imundo LF, Levy DM (2006) Favorable response to high-dose infliximab for refractory childhood uveitis. Ophthalmol 113:860–864, Epub 15 March 2006
Suhler EB, Smith JR, Wertheim MS, Lauer AK, Kurz DE, Pickard TD, Rosenbaum JT (2005) A prospective trial of infliximab therapy for refractory uveitis: preliminary safety and efficacy outcomes. Arch Ophthalmol 123:903–912
Rajaraman RT, Kimura Y, Li S, Haines K, Chu DS (2006) Retrospective case review of pediatric patients with uveitis treated with infliximab. Ophthalmology 113:308–314
Sukumaran S, Marzan K, Shaham B, Reiff A (2012) High dose infliximab in the treatment of refractory uveitis: does dose matter? Rheumatol Jan 5. doi:10.5402/2012/765380
Biester S, Deuter C, Michels H, Haefner R, Kuemmerle-Deschner J, Doycheva D, Zierhut M (2007) Adalimumab in the therapy of uveitis in childhood. Br J Ophthalmol 91:319–324
Foeldvari I, Nielsen S, Kümmerle-Deschner J, Espada G, Horneff G, Bica B, Olivieri AN, Wierk A, Saurenmann RK (2007) Tumor necrosis factor-alpha blocker in treatment of juvenile idiopathic arthritis associated uveitis refractory to second-line agents: results of a multinational survey. J Rheumatol 34:1146–1150
Giannini EH, Ruperto N, Ravelli A, Lovell DJ, Felson DT, Martini A (1997) Preliminary definition of improvement in juvenile arthritis. Arthritis Rheum 40:1202–1209
Petty RE, Southwood TR, Baum J, Bhettay E, Glass DN, Manners P, Maldonado-Cocco J, Suarez-Almazor M, Orozco-Alcala J, Prieur AM (1998) Revision of the proposal classification criteria for juvenile idiopathic arthritis: Durban, 1997. J Rheumatol 25:1991–1994
Jabs DA, Nussenblatt RB, Rosenbaum JT (2005) Standardization of Uveitis Nomenclature (SUN) working group. Standardization of Uveitis Nomenclature for reporting clinical data. Results of the first international workshop. Am J Ophthalmol 140:509–516
Zulian F, Balzarin M, Falcini F, Martini G, Alessio M, Cimaz R, Cimino L, Zannin ME (2010). Abatacept for severe anti-TNF alpha refractory juvenile idiopathic arthritis-related uveitis. Arthritis Care Res (Hoboken) 62(6):821–825
Díaz-Llopis M, Salom D, Garcia-de-Vicuña C, Cordero-Coma M, Ortega G, Ortego N, Suarez-de-Figueroa M, Rio-Pardo MJ, Fernandez-Cid C, Fonollosa A, Blanco R, Garcia-Aparicio AM, Benitez-Del-Castillo JM, Olea JL, Arevalo JF (2012) Treatment of refractory uveitis with adalimumab: a prospective multicenter study of 131 patients. Ophthalmology 119:1575–1581
Tynjälä P, Kotaniemi K, Lindahl P, Latva K, Aalto K, Honkanen V, Lahdenne P (2008) Adalimumab in juvenile idiopathic arthritis-associated chronic anterior uveitis. Rheumatology (Oxford) 47:339–344
Kotaniemi K, Säilä H, Kautiainen H (2011) Long-term efficacy of adalimumab in the treatment of uveitis associated with juvenile idiopathic arthritis. Clin Ophthalmol 5:1425–1429
Vazquez-Cobian LB, Flynn T, Lehman TJ (2006) Adalimumab therapy for childhood uveitis. J Pediatr 149:572–575
Simonini G, Taddio A, Cattalini M, Caputo R, De Libero C, Naviglio S, Bresci C, Lorusso M, Lepore L, Cimaz R (2011) Prevention of flare recurrences in childhood-refractory chronic uveitis: an open-label comparative study of adalimumab versus Infliximab. Arthritis Care Res (Hoboken) 63:612–618
Weinblatt ME, Keystone EC, Furst DE, Kavanaugh AF, Chartash EK, Segurado OG (2006) Long term efficacy and safety of adalimumab plus methotrexate in patients with rheumatoid arthritis: ARMADA 4 year extended study. Ann Rheum Dis 65:753–759
Wolf MD, Lichter PR, Ragsdale CG (1987) Prognostic factors in the uveitis of juvenile rheumatoid arthritis. Ophthalmology 94:1242–1248
Kanski JJ (1992) Lensectomy for complicated cataract in juvenile chronic iridocyclitis. Br J Ophthalmol 76:72–75
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Magli, A., Forte, R., Navarro, P. et al. Adalimumab for juvenile idiopathic arthritis-associated uveitis. Graefes Arch Clin Exp Ophthalmol 251, 1601–1606 (2013). https://doi.org/10.1007/s00417-013-2275-x
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00417-013-2275-x